Science Exchange Appoints Two New Executives to Accelerate Growth
Science Exchange, the leading marketplace for outsourced R&D™, has appointed senior team members Rob Mihalko as Vice President of Marketing and Alex Slater as Vice President of Business Development and General Manager Europe. Both executives, reporting to Science Exchange CEO Elizabeth Iorns, Ph.D., will add to an already talented management team that is driving industry-leading solutions to improve the quality and efficiency of scientific research around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180614005633/en/
Rob Mihalko, Vice President of Marketing, Science Exchange (Photo: Business Wire)
Rob Mihalko is a leading expert in business commerce and procurement and has extensive experience in successfully implementing go-to-market strategies for business-to-business marketplaces on a global scale. As VP of Marketing, Mihalko will be responsible for Science Exchange’s worldwide marketing activities. He will lead the way in aligning Science Exchange’s brand and product positioning with global marketing programs to boost awareness, sales and adoption of the company's industry-leading R&D marketplace.
Prior to joining Science Exchange, Mihalko was Global Vice President of Solution & Customer Marketing for SAP Ariba, where he led marketing and product initiatives that transformed SAP Ariba into the world’s leading procurement and business commerce company. He also has held several senior marketing, product and finance roles with leading technology companies, including Microsoft, and was a management consultant with A.T. Kearney, advising senior executives on strategy, sourcing and supply chain transformation initiatives.
“I’m delighted to have joined such a passionate and mission-driven team at Science Exchange,” said Mihalko. “I’m looking forward to helping the company build on its leadership position in the outsourced research market and support its growth in new verticals and geographies.”
As a VP of Business Development and General Manager Europe, Alex Slater will be spearheading Science Exchange’s continued expansion into the European market. Slater brings 23 years of business development experience within contract research organizations to Science Exchange, spanning the entirety of drug discovery, from basic research to clinical development. He has also led business development teams in Europe and Asia for Covance and, most recently, was the VP Global Business Development at Eurofins Pharma Discovery Services.
In his new role, Slater will provide key leadership and support of Science Exchange’s business development and expansion efforts in Europe. He will work with the global business development team to stimulate provider and researcher recruitment and expand the European support team that will give researchers the personalized scientific support they expect.
“From my initial interactions with Elizabeth Iorns and the team at Science Exchange, I was impressed by their passion and commitment to simplifying researchers’ access to the services they need,” said Slater. “I look forward to working with such a driven team and helping expand the company’s European presence.”
“We work in a rapidly changing environment, and so it’s critical for us to hire people that share our ambitious vision and have the expertise to help us execute it successfully,” said Elizabeth Iorns, CEO of Science Exchange. “I’m thrilled to be welcoming our two new team members, who each bring vast experience to Science Exchange, and I look forward to working closely with them in our mission to enable scientific breakthroughs through connections."
About Science Exchange
Science Exchange is the world's leading and most secure platform for outsourced research, providing large R&D organizations with the fastest path from discovery through development and commercialization. Science Exchange includes an efficient source-to-secure platform for ordering 6,000+ services from a network of more than 2,500 qualified outsourced research providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange.
Gursatya "Guru" Singh
Director of Scientific Content
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
GHX Exhibiting at MEDICA 2018 – World Forum for Healthcare15.10.2018 08:00 | Pressemelding
Global Healthcare Exchange (GHX), a leader in cloud-based healthcare supply chain management solutions, will be exhibiting at the leading international trade fair for the medical sector, MEDICA 2018, in Düsseldorf, Germany between the 12th and 15th November, 2018. GHX provides a full range of intelligent eCommerce and supply chain solutions specifically designed for the complex world of healthcare. The organisation’s technology connects thousands of healthcare suppliers, manufacturers and distributors with hospitals and GPOs – as well as to Governments for reporting processes. GHX technology enables the right devices, equipment, services and medicines to flow efficiently through the European healthcare supply chain. MEDICA attendees are invited to visit GHX in Hall 16, Stand F20-2, to discover how the organisation’s deep commitment to the healthcare industry, unrivalled understanding of the sector and proactive approach to collaboration to develop best practice, ensures its technology
Intertops Poker satellite sending another winner to the Malta Poker Festival where €500K is guaranteed!15.10.2018 07:06 | Pressemelding
Intertops Poker is sending another online satellite tournament winner to play in the €500,000 guaranteed Malta Poker Festival Main Event that runs from November 1st – 6th at the Portamaso Casino. The $2,500 prize package covers the winner’s buy-in to the Malta Poker Festival Main Event, Day 1C. $500 toward travel expenses is included. The online champion will stay at the posh Hilton Hotel November 2 – 7th. The Intertops team will take them to an exclusive MPF VIP party. The Poker Manager at Intertops Poker, said: “The Malta Poker Festival is a brand new event but I am sure it will be a hit, and there is still chance for players to earn their seat at the tables for the main event. “The festival has it all; it is set in a stunning location, it is playing in a prestigious casino and it has a life-changing prize pot. So if you think you have what it takes to lift the trophy, sign-up for the satellite now. Satellites: To register, open the Intertops Poker lobby, click ‘Poker’ > ‘Tournaments
Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke Congress15.10.2018 07:00 | Pressemelding
Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 October 2018. These primary analyses will contribute to the scientific community’s understanding of both disease states and the clinical profile of dabigatran etexilate (Pradaxa®). The results from RE-SPECT ESUS, the first randomised trial comparing dabigatran etexilate with acetylsalicylic acid (ASA) in any indication, will add further insight into the prevention of secondary stroke in patients with an embolic stroke of undetermined source (ESUS).1 As the first comparison to ASA, this trial will also offer further important insights into the clinical profile of dabigatran etexilate. RE-SPECT CVT will provide additional knowledge regarding treatment of patients with cerebral venous thrombosis (CVT).2 It is the first exploratory, prospective, randomised controlled study of any non-vitamin K anta
IFC and Alipay Announce 10x1000 Tech for Inclusion Programme to Inspire Technology Leaders in Emerging Markets15.10.2018 04:15 | Pressemelding
International Financial Corporation (“IFC”), a member of the World Bank Group, and Ant Financial Services Group (“Ant Financial”), the world’s leading tech company and the operator of Alipay, jointly announced the 10x1000 Tech for Inclusion programme at the 2018 Annual Meetings of the International Monetary Fund and the World Bank Group. The initiative will include a comprehensive programme that embraces interactivity and the exchange of ideas to provide training to 10,000 tech experts in emerging markets from both public and private sectors over the next 10 years. Alibaba Group founder and Executive Chairman Jack Ma said that the programme aims to build an interactive and open platform to increase support for tech leaders and skilled individuals who are working to alleviate poverty and make basic financial services more broadly accessible in Indonesia, which will be the first stop of the programme within emerging markets. “I believe that investing in people is investing for the future
Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 201815.10.2018 03:00 | Pressemelding
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that results from the phase III study of satralizumab (development code: SA237), SAkuraSky Study (NCT02028884), were presented at the Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018 held in Berlin, Germany from October 10 to 12. Satralizumab is a humanized investigational recycling anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments. “These positive pivotal results for satralizumab, showing a significant reduction in relapses in patients, are a significant positive step in the potential treatment of NMOSD,” said Dr. Takashi Yamamura, Director, Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo. “Many people with NMOSD are suffering from frequent relapses and often persistent motor dysfunction and loss of sensation, and end up r
Guidewire InsuranceSuite Positioned as a Leader in Gartner's Magic Quadrant for P&C Core Platforms, North America, for Second Consecutive Year14.10.2018 17:10 | Pressemelding
GUIDEWIRE CONNECTIONS 2018–- Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced that Guidewire InsuranceSuite™ has been recognized as a Leader in Gartner, Inc.'s “Magic Quadrant for P&C Core Platforms, North America 1 .” InsuranceSuite comprises essential core systems based on a common technology platform covering the P&C insurance lifecycle including underwriting, policy, billing, and claims management. It was positioned highest on the ability to execute axis and furthest on the completeness of vision axis in the report. The report can be viewed here. “While many vendors are playing to specific strengths, market leaders are expanding the scope of their capabilities with a growing emphasis on broader ecosystems with partners accessible through prebuilt integration in an app-store-like venue. As the number of ecosystem partners grows, this promises customers quicker access to a range of new capabilitie